Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $23.1 million.

  • Axsome Therapeutics' Share-based Compensation rose 6.66% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year increase of 13.22%. This contributed to the annual value of $85.2 million for FY2024, which is 36.09% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Share-based Compensation of $23.1 million as of Q3 2025, which was down 6.13% from $24.6 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Share-based Compensation high stood at $24.6 million for Q2 2025, and its period low was $9,197 during Q3 2022.
  • In the last 3 years, Axsome Therapeutics' Share-based Compensation had a median value of $21.4 million in 2024 and averaged $20.0 million.
  • Data for Axsome Therapeutics' Share-based Compensation shows a peak YoY surged of 177,871.08% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Share-based Compensation (Quarterly) stood at $10.8 million in 2022, then skyrocketed by 75.66% to $18.9 million in 2023, then grew by 16.24% to $22.0 million in 2024, then climbed by 6.66% to $23.1 million in 2025.
  • Its Share-based Compensation was $23.1 million in Q3 2025, compared to $24.6 million in Q2 2025 and $23.3 million in Q1 2025.